AlphaFold Accelerates Artificial Intelligence Powered Drug Discovery: Efficient Discovery of a Novel Cyclin-dependent Kinase 20 (CDK20) Small Molecule Inhibitor

• URL: http://arxiv.org/abs/2201.09647v1
• Date: Fri, 21 Jan 2022 07:35:24 GMT
• Title: AlphaFold Accelerates Artificial Intelligence Powered Drug Discovery: Efficient Discovery of a Novel Cyclin-dependent Kinase 20 (CDK20) Small Molecule Inhibitor
• Authors: Feng Ren, Xiao Ding, Min Zheng, Mikhail Korzinkin, Xin Cai, Wei Zhu, Alexey Mantsyzov, Alex Aliper, Vladimir Aladinskiy, Zhongying Cao, Shanshan Kong, Xi Long, Bonnie Hei Man Liu, Yingtao Liu, Vladimir Naumov, Anastasia Shneyderman, Ivan V. Ozerov, Ju Wang, Frank W. Pun, Alan Aspuru-Guzik, Michael Levitt, and Alex Zhavoronkov
• Abstract summary: We successfully applied AlphaFold to identify a first-in-class hit molecule of a novel target without an experimental structure. We identified a small molecule hit compound for CDK20 with a Kd value of 8.9 +/- 1.6 uM within 30 days from target selection and after only 7 compounds. This is the first reported small molecule targeting CDK20 and more importantly, this work is the first demonstration of AlphaFold application in the hit identification process in early drug discovery.
• Score: 9.89420507558956
• License: http://creativecommons.org/licenses/by-nc-sa/4.0/
• Abstract: The AlphaFold computer program predicted protein structures for the whole human genome, which has been considered as a remarkable breakthrough both in artificial intelligence (AI) application and structural biology. Despite the varying confidence level, these predicted structures still could significantly contribute to the structure-based drug design of novel targets, especially the ones with no or limited structural information. In this work, we successfully applied AlphaFold in our end-to-end AI-powered drug discovery engines constituted of a biocomputational platform PandaOmics and a generative chemistry platform Chemistry42, to identify a first-in-class hit molecule of a novel target without an experimental structure starting from target selection towards hit identification in a cost- and time-efficient manner. PandaOmics provided the targets of interest and Chemistry42 generated the molecules based on the AlphaFold predicted structure, and the selected molecules were synthesized and tested in biological assays. Through this approach, we identified a small molecule hit compound for CDK20 with a Kd value of 8.9 +/- 1.6 uM (n = 4) within 30 days from target selection and after only synthesizing 7 compounds. To the best of our knowledge, this is the first reported small molecule targeting CDK20 and more importantly, this work is the first demonstration of AlphaFold application in the hit identification process in early drug discovery.

Related papers

• Aligning Target-Aware Molecule Diffusion Models with Exact Energy Optimization [147.7899503829411]
  AliDiff is a novel framework to align pretrained target diffusion models with preferred functional properties. It can generate molecules with state-of-the-art binding energies with up to -7.07 Avg. Vina Score.
  arXiv  Detail & Related papers  (2024-07-01T06:10:29Z)
• Target Specific De Novo Design of Drug Candidate Molecules with Graph Transformer-based Generative Adversarial Networks [0.0]
  We propose an end-to-end generative system, DrugGEN, for the de novo design of drug candidate molecules. The system is trained using a large dataset of drug-like compounds and target-specific bioactive molecules. Using the open-access DrugGEN, it is possible to easily train models for other druggable proteins.
  arXiv  Detail & Related papers  (2023-02-15T18:59:27Z)
• Tailoring Molecules for Protein Pockets: a Transformer-based Generative Solution for Structured-based Drug Design [133.1268990638971]
  De novo drug design based on the structure of a target protein can provide novel drug candidates. We present a generative solution named TamGent that can directly generate candidate drugs from scratch for a given target.
  arXiv  Detail & Related papers  (2022-08-30T09:32:39Z)
• Widely Used and Fast De Novo Drug Design by a Protein Sequence-Based Reinforcement Learning Model [4.815696666006742]
  Structure-based de novo method can overcome the data scarcity of active by incorporating drug-target interaction into deep generative architectures. Here, we demonstrate a widely used and fast protein sequence-based reinforcement learning model for drug discovery. As a proof of concept, the RL model was utilized to design molecules for four targets.
  arXiv  Detail & Related papers  (2022-08-14T10:41:52Z)
• Improved Drug-target Interaction Prediction with Intermolecular Graph Transformer [98.8319016075089]
  We propose a novel approach to model intermolecular information with a three-way Transformer-based architecture. Intermolecular Graph Transformer (IGT) outperforms state-of-the-art approaches by 9.1% and 20.5% over the second best for binding activity and binding pose prediction respectively. IGT exhibits promising drug screening ability against SARS-CoV-2 by identifying 83.1% active drugs that have been validated by wet-lab experiments with near-native predicted binding poses.
  arXiv  Detail & Related papers  (2021-10-14T13:28:02Z)
• Benchmarking Deep Graph Generative Models for Optimizing New Drug Molecules for COVID-19 [11.853524110656991]
  Design of new drug compounds with target properties is a key area of research in generative modeling. We present a small drug molecule design pipeline based on graph-generative models and a comparison study of two state-of-the-art graph generative models for designing COVID-19 targeted drug candidates.
  arXiv  Detail & Related papers  (2021-02-09T17:49:26Z)
• Chemistry42: An AI-based platform for de novo molecular design [48.40662244096031]
  Chemistry42 is a software platform for de novo small molecule design. It integrates Artificial Intelligence (AI) techniques with computational and medicinal chemistry methods.
  arXiv  Detail & Related papers  (2021-01-22T10:49:26Z)
• Learning To Navigate The Synthetically Accessible Chemical Space Using Reinforcement Learning [75.95376096628135]
  We propose a novel forward synthesis framework powered by reinforcement learning (RL) for de novo drug design. In this setup, the agent learns to navigate through the immense synthetically accessible chemical space. We describe how the end-to-end training in this study represents an important paradigm in radically expanding the synthesizable chemical space.
  arXiv  Detail & Related papers  (2020-04-26T21:40:03Z)
• CogMol: Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative Models [74.58583689523999]
  We propose an end-to-end framework, named CogMol, for designing new drug-like small molecules targeting novel viral proteins. CogMol combines adaptive pre-training of a molecular SMILES Variational Autoencoder (VAE) and an efficient multi-attribute controlled sampling scheme. CogMol handles multi-constraint design of synthesizable, low-toxic, drug-like molecules with high target specificity and selectivity.
  arXiv  Detail & Related papers  (2020-04-02T18:17:20Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.